Andro Targeted By FDA In Coordination With Capitol Hill Action
This article was originally published in The Tan Sheet
Executive Summary
FDA is aiming to remove androstenedione supplements from the market by classifying the substance as a new dietary ingredient that has not been the subject of a safety notification to the agency, as required by the Dietary Supplement Health & Education Act